Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
64 hedge funds and large institutions have $88.7M invested in Kindred Biosciences, Inc. in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
14% more funds holding
Funds holding: 56 → 64 (+8)
9% less capital invested
Capital invested by funds: $97.9M → $88.7M (-$9.22M)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
60% less call options, than puts
Call options by funds: $4K | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
+$2.54M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$2.54M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$1.14M |
| 4 |
LCM
Leonard Capital Management
Vero Beach,
Florida
|
+$975K |
| 5 |
JIC
Johnson Investment Counsel
Cincinnati,
Ohio
|
+$535K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$2.17M |
| 2 |
Morgan Stanley
New York
|
-$2.16M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$1.91M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.62M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.22M |
KIN Hedge Fund Activity: Q4 2014 in Review
64 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2014, worth a combined $88.7M — down 9.4% from $97.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KIN positions and 8 closed out — a net gain of 10 holders — while 18 added to existing stakes and 20 trimmed.
The largest buyer was Gruss Capital Management, opening a new position worth an estimated $2.54M. The largest seller was Park West Asset Management, exiting entirely with an estimated $2.17M sold.
- 64 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2014, up from 56 in Q3 2014.
- Funds reported $88.7M of Kindred Biosciences, Inc. stock for Q4 2014, down 9.4% quarter-over-quarter.
- 18 funds opened new Kindred Biosciences, Inc. positions in Q4 2014 and 8 closed out, a net change of +10 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2014 was Gruss Capital Management, an estimated $2.54M added.
- The largest Kindred Biosciences, Inc. seller in Q4 2014 was Park West Asset Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2014.